Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering

2 weeks ago

WATERTOWN, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new…

Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering

2 weeks ago

WATERTOWN, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new…

Terns Announces Pricing of Upsized $650 Million Public Offering

2 weeks ago

FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage…

Terns Announces Pricing of Upsized $650 Million Public Offering

2 weeks ago

FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage…

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

2 weeks ago

SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel…

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

2 weeks ago

SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel…

Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

2 weeks ago

CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on…

Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

2 weeks ago

CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on…

Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock

2 weeks ago

WALTHAM, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement…

Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock

2 weeks ago

WALTHAM, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement…

Show more Posts
Show previous Posts